Literature DB >> 23697684

Ellipticine binds to a human telomere sequence: an additional mode of action as a putative anticancer agent?

Saptaparni Ghosh1, Anirban Kar, Shantanu Chowdhury, Dipak Dasgupta.   

Abstract

Polyguanine sequences fold into G-quadruplex structures in the presence of monovalent cations. It is accepted that the telomeric DNA region consists of G-quadruplex structure. There are reports that potential G-quadruplex forming motifs are also present in the promoter region of some proto-oncogenes such as c-myc, c-kit, KRAS, etc. Small molecules with the potential to stabilize the telomeric DNA quadruplex have emerged as potential anticancer agents. We have studied the interaction of ellipticine, a putative anticancer agent from a plant source, with a human telomeric DNA sequence (H24). Spectroscopic and calorimetric studies indicate that the association of ellipticine with H24 is an entropically driven phenomenon with a 2:3 (H24:ellipticine) stoichiometry. Though ellipticine binding does not induce any major structural perturbation in H24, the association leads to formation of a complex with enhanced thermal stability. An assay with the telomerase repeat amplification protocol shows that ellipticine inhibits telomerase activity in MDAMB-231 breast cancer cell line extracts. This is the first report of the quadruplex binding ability of ellipticine. Using the results, we propose that along with DNA intercalation and/or topoisomerase II inhibition, interaction with the telomeric DNA region and the resultant inhibition of telomerase activity might be an additional mode of action for its anticancer property.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23697684     DOI: 10.1021/bi400080t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells.

Authors:  Jing-Ping Wang; Ya-Chu Yu; Shih-Ping Chen; Huan-Chang Liang; Chia-Wei Lin; Kang Fang
Journal:  Mol Cell Biochem       Date:  2015-05-27       Impact factor: 3.396

2.  Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.

Authors:  Amanda J Pickard; Fang Liu; Thomas F Bartenstein; Laura G Haines; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Chemistry       Date:  2014-10-10       Impact factor: 5.236

Review 3.  The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.

Authors:  Marie Stiborová; Věra Černá; Michaela Moserová; Iveta Mrízová; Volker M Arlt; Eva Frei
Journal:  Int J Mol Sci       Date:  2014-12-25       Impact factor: 5.923

4.  Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.

Authors:  Vishnu Muthuraj Kumarasamy; Daekyu Sun
Journal:  Int J Oncol       Date:  2017-05-11       Impact factor: 5.650

5.  ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer.

Authors:  Shuixiang Tao; Shuai Meng; Xiangyi Zheng; Liping Xie
Journal:  Mol Med Rep       Date:  2017-01-24       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.